Dalton Greiner Hartman Maher & Co. raised its holdings in Smith & Nephew plc (NYSE:SNN) by 236.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 198,696 shares of the medical equipment provider’s stock after buying an additional 139,673 shares during the quarter. Dalton Greiner Hartman Maher & Co.’s holdings in Smith & Nephew were worth $9,563,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. LS Investment Advisors LLC acquired a new stake in Smith & Nephew in the 2nd quarter valued at approximately $31,000. Advisory Services Network LLC grew its holdings in Smith & Nephew by 132.7% in the 2nd quarter. Advisory Services Network LLC now owns 819 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 467 shares during the last quarter. Oakworth Capital Inc. acquired a new stake in Smith & Nephew in the 2nd quarter valued at approximately $42,000. Pinnacle Bank grew its holdings in Smith & Nephew by 27.6% in the 3rd quarter. Pinnacle Bank now owns 1,063 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 230 shares during the last quarter. Finally, SRS Capital Advisors Inc. acquired a new stake in Smith & Nephew in the 2nd quarter valued at approximately $54,000. 8.76% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have issued reports on the company. ValuEngine lowered Smith & Nephew from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Zacks Investment Research lowered Smith & Nephew from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Berenberg Bank raised Smith & Nephew from a “hold” rating to a “buy” rating in a report on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company’s stock. Smith & Nephew has a consensus rating of “Hold” and a consensus price target of $27.50.

Shares of NYSE:SNN traded down $0.03 during trading on Thursday, hitting $46.77. 54,178 shares of the stock were exchanged, compared to its average volume of 549,860. Smith & Nephew plc has a 1-year low of $32.22 and a 1-year high of $48.93. The company has a market capitalization of $20.62 billion, a price-to-earnings ratio of 23.16, a price-to-earnings-growth ratio of 3.24 and a beta of 0.25. The company’s fifty day simple moving average is $47.49 and its 200-day simple moving average is $43.65. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.96 and a current ratio of 2.00.

The company also recently disclosed a — dividend, which will be paid on Wednesday, October 30th. Stockholders of record on Friday, October 4th will be issued a dividend of $0.288 per share. This represents a dividend yield of 1.5%. The ex-dividend date is Thursday, October 3rd. Smith & Nephew’s payout ratio is presently 27.72%.

Smith & Nephew Company Profile

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Featured Story: How is a price target determined?

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.